Hosted on MSN2d
ADMA Loses 8.9% in a Month: How Should You Play the Stock?ADMA Biologics’ ADMA shares have lost 8.9% in a month against the industry’s growth of 6.6%. The company has put up a ...
FDA’s Rare Disease Innovation Hub Releases Strategic Agenda: Implications for Stakeholders in 2025
In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
LUND, SE / ACCESS Newswire / February 6, 2025 / Alligator Bioscience (STO:ATORX) FDA feedback validates the clinical ...
HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...
The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has ...
This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...
United Therapeutics (UTHR) announced that the FDA has cleared its investigational new drug application to initiate a clinical study of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback